A Stochastic Economic Evaluation of Letrozole versus Tamoxifen as a First-Line Hormonal Therapy
- 1 January 2003
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 21 (7) , 513-525
- https://doi.org/10.2165/00019053-200321070-00006
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breastJournal of Surgical Oncology, 2001
- Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer GroupJournal of Clinical Oncology, 2001
- Systematic Overview of Cost-Utility Assessments in OncologyJournal of Clinical Oncology, 2000
- Economic Evaluation of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in CanadaValue in Health, 2000
- Sensitivity Analysis and the Expected Value of Perfect InformationMedical Decision Making, 1998
- A New Decision Model for Cost-Utility Comparisons of Chemotherapy in Recurrent Metastatic Breast CancerPharmacoEconomics, 1996
- ABC of Breast Diseases: Metastatic breast cancerBMJ, 1994
- Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast CancerJAMA, 1992
- Endocrine therapy for advanced breast cancer: A reviewBreast Cancer Research and Treatment, 1992
- The impact of a breast cancer screening programme on quality‐adjusted life‐yearsInternational Journal of Cancer, 1991